Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

Disparities have been described in various domains of cancer research, each issue exists separately and has a different relationship to understanding and addressing disparities in clinical outcomes. The various domains of research disparities are explored in Cancer Research and Disparities: Understanding and Addressing the Issues. 

ACS CAN submitted comments to the National Institute of Health Request for Information: Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research

ACS CAN submitted comments to Medicare Administrative Contractors proposing coverage for minimal residual disease testing for cancer. 

Precision medicine in cancer involves targeted therapies which work by interfering with specific cellular processes involved in the growth, spread, and progression of cancer. Treatment with targeted therapy often requires diagnostic testing to identify specific cancer biomarkers. Testing patients for biomarkers is integral to precision medicine in cancer care.

Every five years the FDA drug user fees are reauthorized, offering an opportunity to influence priorities.  ACS CAN is recommending an increased focus on patient representation in regulatory decision making, guidance to drive increased use of decentralized trials, and a scientific focus on dispar

Advances in precision medicine have led to targeted cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, many cancer patients are not tested for biomarkers. This fact sheet highlights recent advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing.  

Research is critical to understanding and reducing cancer disparities, as well as examining gaps in cancer prevention and care delivery that contribute to these disparities. Clinical trials are a key part of research and enable the development of better drugs and treatments for cancer.

The U.S. Food and Drug Administration's (FDA's) typically follows a standard review process to evaluate a drug’s safety and efficacy. However, drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. This factsheet describes those programs.  

A significant portion of the U.S. Food and Drug Administration's (FDA's) operating budget comes from user fees paid by industry.  The authority to collect these fees expires every five years and must be renewed.  This factsheet describes the program.